Lale White
Cardiff OncologyAbout Lâle White
Independent director of Cardiff Oncology, Inc. since April 2020; age 69 as of April 28, 2025. Chief Executive Officer of XIFIN, Inc. with 25+ years in healthcare information systems and medical billing; previously VP of Finance at Laboratory Corporation of America and predecessor National Health Laboratories. Education: BA in finance and MBA from Florida International University. Serves as Audit Committee Chair and audit committee financial expert; Board has determined she is independent under Nasdaq and SEC rules.
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Laboratory Corporation of America / National Health Laboratories | Vice President of Finance | Not disclosed | Led development of AR, inventory, cost accounting, and financial management systems for lab industry |
| bioTheranostics (BioMérieux subsidiary) | Board member (previously) | Not disclosed | Governance for a molecular diagnostics subsidiary |
| CombiMatrix Corporation | Board member (prior public company) | Until acquisition by Invitae in 2017 | Board service; company later acquired |
| HCFA & U.S. Office of Inspector General | Consultant | Not disclosed | Helped develop first OIG Model Compliance Program |
External Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| XIFIN, Inc. | Chief Executive Officer | Current | Leadership of financial cloud computing company for healthcare billing |
| California Clinical Lab Association | Member; chairs state and federal contractor committees | 8 years chairing | Works with Medicare Administrative Contractors and HHS |
Board Governance
- Committee assignments: Audit Committee Chair; Audit members include White (Chair), Rodney S. Markin, and Mani Mohindru; White designated audit committee financial expert.
- Independence: Board determined White is independent under Nasdaq Listing Rule 5605 and SEC criteria.
- Attendance: In 2024, Board held 18 meetings; Audit 4; Compensation 3; Governance/Nominating 5; no director attended fewer than 95% of aggregate Board and committee meetings. Independent directors meet separately without management on a regular basis.
- Anti-hedging: Insider Trading Policy prohibits hedging transactions for employees, officers, and directors.
- Equity plan governance: No repricing without stockholder approval; no evergreen; no tax gross-ups; minimum 1-year vesting (up to 5% exception); clawback applies to awards; director compensation cap $500,000 ($750,000 in initial year).
Fixed Compensation
| Component | Amount | Notes |
|---|---|---|
| Board annual retainer – Chair (cash) | $105,000 | Not applicable to White (not Board Chair) |
| Board annual retainer – Member (cash) | $65,000 | Baseline for non-employee directors |
| Committee annual retainer – Audit Chair | $16,000 | Applies to White |
| Committee annual retainer – Audit Member | $8,000 | — |
| Committee annual retainer – Compensation Chair | $10,000 | — |
| Committee annual retainer – Compensation Member | $6,000 | — |
| Committee annual retainer – Governance/Nominating Chair | $8,000 | — |
| Committee annual retainer – Governance/Nominating Member | $4,000 | — |
| 2024 Director Compensation (White) | Amount ($) |
|---|---|
| Fees earned or paid in cash | 81,000 |
| Option awards (grant-date fair value) | 56,460 |
| Total | 137,460 |
Performance Compensation
| Annual Equity Grant (Continuing Directors, 2024) | Detail |
|---|---|
| Option shares | 29,700 options |
| Exercise price | $2.33 |
| Vesting | 100% on one-year anniversary of grant |
| Award type | Non-employee director annual option grant |
| Clawback applicability | Awards subject to recoupment/clawback under certain circumstances |
| Repricing | Not permitted without stockholder approval |
No performance-based (metric-linked) components are disclosed for director compensation; director option grants are time-vested.
Other Directorships & Interlocks
| Company | Public/Private | Role | Notes |
|---|---|---|---|
| CombiMatrix Corporation | Public (prior) | Director | Board service until acquisition by Invitae in 2017 |
| bioTheranostics (BioMérieux subsidiary) | Private/subsidiary | Director (previously) | Board role at a diagnostics subsidiary |
No related-party transactions involving White were disclosed for 2024–2025.
Expertise & Qualifications
- Healthcare revenue cycle and reimbursement operations; extensive medical billing systems expertise.
- Financial leadership and systems development across large clinical laboratories.
- Regulatory compliance experience (OIG Model Compliance Program).
- Audit committee financial expertise per SEC/Nasdaq definition.
Equity Ownership
| Metric | Value |
|---|---|
| Beneficial ownership (shares) | 231,904 (includes options exercisable within 60 days) |
| % of shares outstanding | <1% (based on 66,525,854 shares as of April 28, 2025) |
| Options outstanding (as of 12/31/2024) | 118,116 total; 88,416 exercisable |
| Options exercisable within 60 days (as of 4/28/2025) | 118,116 |
| Anti-hedging/pledging | Hedging prohibited by policy; no pledging disclosures noted for directors |
Insider Trades (Cardiff Oncology)
| Filing Date | Transaction Date | Form | Transaction | Shares | Price | Link |
|---|---|---|---|---|---|---|
| Jul 1, 2024 | Jun 27, 2024 | Form 4 | Grant of stock options (annual director grant) | 29,700 | $2.33 (exercise) |
Additional Form 4 filed June 27, 2025 (details available in EDGAR); the company maintains historical SEC filings index.
Governance Assessment
- Strengths: Independent Audit Committee Chair with designated financial expert status; high attendance; anti-hedging policy; clear director compensation caps; no related-party transactions disclosed. These factors support board effectiveness and investor confidence.
- Compensation alignment: Director pay is modest and balanced between cash retainers and time-vested options; no tax gross-ups; no repricing without stockholder approval; clawback applies to awards.
- Shareholder oversight context: Equity plan governance highlights (no evergreen, minimum vesting) and transparent burn/overhang reporting; overhang was 17.3% as of March 31, 2025, with proposed share increase discussed—an area investors may monitor for dilution risk.
- RED FLAGS: None identified specific to White (no related-party dealings; no attendance issues; no hedging/pledging disclosed). Broader equity overhang/dilution is a company-level consideration rather than director-specific.
Say-on-pay: Stockholders opted for annual advisory votes at the 2023 meeting; 2025 advisory vote scheduled (Proposal 4). Not directly tied to director pay but relevant to compensation governance.
